ORCHPHARMA
Orchid Pharma share price & financials
- Price
- ₹979.05
- Market cap
- ₹6.2k Cr
- Sector
- Healthcare
- Calls analysed
- 8
Orchid Pharma Limited Q1 FY27
What went well
- Revenue from operations grew 15% YoY to INR304 crores in Q1 FY27.
- Combined gross margin improved by 3 percentage points to 33% in Q1 FY27.
- EBITDA increased significantly to INR25 crores in Q1 FY27 from INR10 crores in Q1 FY26.
What to watch
- FY26 was a difficult year for the cephalosporin business, with volumes and pricing affected by 15-20% declines.
- Industry still faces overcapacities leading to cutthroat competition, particularly in non-regulated markets.
What Orchid Pharma Limited does
Orchid Pharma manufactures and exports cephalosporin antibiotic active pharmaceutical ingredients (APIs) spanning all five generations, along with finished dosage formulations (oral and sterile injectables) and veterinary products, earning through global regulated and emerging-market sales. It also develops and licenses its own novel antibiotic molecule (Enmetazobactam, branded EXBLIFEP/Orblicef) invented in-house. The company operates a single reported business segment - cephalosporin pharmaceuticals - and is vertically integrating backward into 7-ACA (a key fermentation-derived intermediate) to reduce import dependence.
Segments
- Cephalosporin Pharmaceuticals
- One of only three USFDA-approved sterile cephalosporin manufacturing facilities in the world
- 1 of 3 globally
- Cephalosporin product range covered
- 44 of 50 cephalosporins ever invented
- API manufacturing complex
- Alathur, near Chennai, Tamil Nadu - one of India's largest integrated antibiotic manufacturing complexes
- Facility size and blocks
- 60-acre facility with 5 sterile and 7 oral production blocks
- US Drug Master Filings (DMF)
- 48 cumulative (30 Cephalosporin, 18 NPNC segment)
- ANDAs held (US)
- 6
Guidance record · Q1 FY27
what the last two calls moved 25 tracked 0 delivered 11 missed 14 open- Enmetazobactam Lifetime Sales went quiet said Q2 FY25 Promised: $2 billion to $3 billion Q1 FY27: The overall lifetime sales target of $1-2 billion was not mentioned. Management provided a 10-year value of ~$178 million for a specific licensing arrangement in Russia.
- Teflaro & Avycaz US Filing delayed said Q3 FY26 Promised: This year or early next year Q1 FY27: Regarding Zavicefta (Avycaz), management now expects 'validation batches maybe this year or early next year, and then six months for filing.' This pushes the filing timeline to mid-to-late 2027, beyond the original target.
- 7ACA Plant Commissioning on track said Q2 FY25 Promised: April '26 Q1 FY27: We target commissioning by December of '26, followed by validation and initial batches during January to March '27 period. Our objective remains unchanged, commissioning and the first commercial batch by March of '27.
All 25 tracked — every revision, and every one management stopped mentioning.
Open the guidance ledgerQuarterly results
Q1 FY27: revenue up 15.6%, net profit up 156.6% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 223 | 217 | 237 | 263 | 194 −13% | 207 −5% | 368 +55% | 304 +16% |
| EBITDA | 30 | 26 | 28 | -6 | -1 −105% | 2 −94% | 30 +8% | 14 +348% |
| Net profit | 27 | 21 | 22 | -6 | -6 −121% | -13 −161% | 26 +16% | 3 +157% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Performance +40.4% 1Y
1Y: ₹714.6 on 10 Sept 2025 → ₹1,003.05. High ₹1,101.4 (15 Jul 2026), low ₹482.45 (30 Mar 2026).
How the price took the results
close before → close after
- Q1 FY27
- +3.6%
- 24 Aug
- Q4 FY26
- −1.9%
- 1 Jun
- Q3 FY26
- −2.6%
- 12 Feb
- Q2 FY26
- −2.7%
- 11 Nov
The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.
Financials, as filed
Revenue grew 15.7% a year over 3 years, FY23 to FY26. Operating margin narrowed to 2.4%.
| Year ending | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| Revenue | ₹666 Cr | ₹819 Cr | ₹922 Cr | ₹1.0k Cr |
| Operating profit | ₹84 Cr | ₹110 Cr | ₹117 Cr | ₹25 Cr |
| Operating margin | 12.6% | 13.4% | 12.7% | 2.4% |
| Interest | ₹32 Cr | ₹16 Cr | ₹15 Cr | ₹11 Cr |
| Depreciation | ₹55 Cr | ₹33 Cr | ₹35 Cr | ₹39 Cr |
| Net profit | ₹47 Cr | ₹92 Cr | ₹100 Cr | ₹2 Cr |
| Net margin | 7.0% | 11.2% | 10.8% | 0.2% |
| Cash from operations | ₹18 Cr | ₹126 Cr | ₹19 Cr | ₹101 Cr |
| Free cash flow | ₹-8 Cr | ₹61 Cr | ₹-131 Cr | ₹-273 Cr |
| ROCE | 5.0% | 9.0% | 8.0% | 2.0% |
How to read this
From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.
Balance sheet
| Year ending | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Equity capital | ₹41 Cr | ₹41 Cr | ₹41 Cr | ₹51 Cr | ₹51 Cr | ₹51 Cr |
| Reserves | ₹612 Cr | ₹607 Cr | ₹648 Cr | ₹1.1k Cr | ₹1.2k Cr | ₹1.2k Cr |
| Borrowings | ₹453 Cr | ₹268 Cr | ₹331 Cr | ₹135 Cr | ₹282 Cr | ₹363 Cr |
| Other liabilities | ₹132 Cr | ₹195 Cr | ₹205 Cr | ₹249 Cr | ₹167 Cr | ₹261 Cr |
| Total liabilities | ₹1.2k Cr | ₹1.1k Cr | ₹1.2k Cr | ₹1.6k Cr | ₹1.7k Cr | ₹1.9k Cr |
| Fixed assets | ₹670 Cr | ₹584 Cr | ₹573 Cr | ₹620 Cr | ₹631 Cr | ₹692 Cr |
| Capital work in progress | ₹7 Cr | ₹10 Cr | ₹46 Cr | ₹31 Cr | ₹120 Cr | ₹341 Cr |
| Investments | ₹15 Cr | ₹45 Cr | ₹44 Cr | ₹46 Cr | ₹49 Cr | ₹53 Cr |
| Other assets | ₹544 Cr | ₹472 Cr | ₹561 Cr | ₹857 Cr | ₹922 Cr | ₹826 Cr |
| Total assets | ₹1.2k Cr | ₹1.1k Cr | ₹1.2k Cr | ₹1.6k Cr | ₹1.7k Cr | ₹1.9k Cr |
How to read this
As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.
Who owns it
As disclosed at Jun 2026
Since Jun 2025, DIIs added +1.32 pp while the public trimmed −0.72 pp. The shareholder count shrank 16% to 33,433.
- Promoters
- 69.8%
- FIIs
- 0.8%
- DIIs
- 20.8%
- Public
- 8.6%
Since Jun 2025
- DIIs +1.32 pp
- Public −0.72 pp
- FIIs −0.59 pp
How it drifted, 12 quarters
Over this window DIIs went from 12.5% to 20.8% — +8.3 pp.
Ownership split by quarter, oldest first. Sep '23: Promoters 72.4%, FIIs 8.1%, DIIs 12.5%, Public 7.0%.Dec '23: Promoters 69.8%, FIIs 4.1%, DIIs 14.5%, Public 11.5%.Mar '24: Promoters 69.8%, FIIs 2.0%, DIIs 17.7%, Public 10.5%.Jun '24: Promoters 69.8%, FIIs 1.4%, DIIs 18.9%, Public 9.8%.Sep '24: Promoters 69.8%, FIIs 1.9%, DIIs 18.3%, Public 9.9%.Dec '24: Promoters 69.8%, FIIs 2.5%, DIIs 19.0%, Public 8.6%.Mar '25: Promoters 69.8%, FIIs 2.7%, DIIs 20.1%, Public 7.4%.Jun '25: Promoters 69.8%, FIIs 1.4%, DIIs 19.4%, Public 9.3%.Sep '25: Promoters 69.8%, FIIs 1.6%, DIIs 19.0%, Public 9.6%.Dec '25: Promoters 69.8%, FIIs 1.2%, DIIs 19.4%, Public 9.6%.Mar '26: Promoters 69.8%, FIIs 0.9%, DIIs 20.2%, Public 9.0%.Jun '26: Promoters 69.8%, FIIs 0.8%, DIIs 20.8%, Public 8.6%.
Who bought this quarter
since Mar 2026
Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.
- Kotak Mahindra Trustee Co Ltd A/C Kotak Consumption Fund And 7 Others Mutual fund newly disclosed 4.60% held
- UTI Small Cap Fund And 3 Others Mutual fund newly disclosed 3.46% held
- Invesco India Contra Fund And 2 Others Mutual fund newly disclosed 2.87% held
- Bandhan Small Cap Fund And 5 Others Mutual fund newly disclosed 1.53% held
The same filing shows 0 holders trimming and 4 off the list — both are in the register beside this.
Who is on the register
Named in the Jun 2026 filing
Every holder of Orchid Pharma Limited above SEBI's 1% disclosure line, and what changed since Mar 2026.
| Holder | Stake | Change |
|---|---|---|
| Dhanuka Laboratories Limited | 69.84% | unchanged |
| Quant Mutual Fund - Quant Small Cap Fund - 2 Mutual fund | 6.83% | unchanged |
| Kotak Mahindra Trustee Co Ltd A/C Kotak Consumption Fund And 7 Others Mutual fund | 4.60% | newly disclosed |
| UTI Small Cap Fund And 3 Others Mutual fund | 3.46% | newly disclosed |
| Invesco India Contra Fund And 2 Others Mutual fund | 2.87% | newly disclosed |
| Bandhan Small Cap Fund And 5 Others Mutual fund | 1.53% | newly disclosed |
| Kotak Mahindra Trustee Co Ltd A/C Kotak Multi Asset Allocation Fund And 5 Others | — | off the list |
| UTI-Healthcare Fund And 3 Others | — | off the list |
| Invesco India Equity Savings Fund And 2 Others | — | off the list |
| Bandhan BSE Healthcare Index Fund And 3 Others | — | off the list |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
All earnings calls (8)
Read the Q1 FY27 call →Learn to analyse Orchid Pharma Limited
Guides on how to read this kind of business and the numbers that matter.